Immunomedics pursues breast imaging

Article

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its clinical trials have demonstrated that the monoclonal antibody-based agent correctly identifies cancer in 82% of the women studied, and in 91%, cancer was correctly ruled out. CEA-Scan is already being sold in the U.S. and Europe for the detection of colorectal cancer.

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Emerging Innovations in Molecular Imaging
Related Content
© 2023 MJH Life Sciences

All rights reserved.